← Eichor
Study identifier: NCT06962800 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Condition: Primary Membranous Nephropathy  ·  Sponsor: Biogen

PhasePhase 3
Planned participants180
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoantibodies in the glomeruli causes damage to the kidneys. Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with PMN. Symptoms of PMN can include swelling in the legs and body, tiredness, and high blood pressure. If left untreated, PMN can eventually lead to kidney failure. In this study, researchers will learn more about how a study drug called felzartamab affects people with PMN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce autoantibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works compared to a drug called tacrolimus. Tacrolimus is another drug given to people with PMN and kidney disease. The main question that researchers want to answer is: * How many participants achieve a complete response after 104 weeks of treatm…

This description comes directly from the study's public registry record.

Talk to the study team

US Biogen Clinical Trial Center  ·  866-633-4636  ·  clinicaltrials@biogen.com

Global Biogen Clinical Trial Center  ·  clinicaltrials@biogen.com

Always discuss trial participation with your own doctor first.

Locations (104)

Apogee Clinical Research, LLCHuntsville, Alabama, United StatesRecruiting
The Nephrology Group, Inc. - FresnoFresno, California, United StatesRecruiting
Academic Medical Research InstituteLos Angeles, California, United StatesRecruiting
UCLA Health Connie Frank Kidney Transplant Center and General NephrologyLos Angeles, California, United StatesRecruiting
UCSF Medical CenterSan Francisco, California, United StatesRecruiting
Stanford UniversityStanford, California, United StatesRecruiting
Henry Ford Hospital- A-Basement Research PharmacyDetroit, Michigan, United StatesRecruiting
Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDSPontiac, Michigan, United StatesCompleted
James J Peters Veterans Administration Medical Center - NAVREF - PPDSThe Bronx, New York, United StatesRecruiting
ECU Physicians Nephrology and HypertensionGreenville, North Carolina, United StatesRecruiting
University Hospitals Cleveland Medical CenterCleveland, Ohio, United StatesRecruiting
Knoxville Kidney Center, PLLCKnoxville, Tennessee, United StatesRecruiting

+ 92 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06962800